References

  1. Turner R, Howseman A, Rees GE, Josephs O, Friston K. Functional magnetic resonance imaging of the human brain: data acquisition and analysis. Exp Brain Res 1998;123:5-12.
  2. Logothetis NK. The neural basis of the blood-oxygen-level-dependent functional magnetic resonance imaging signal. Phil Trans R Soc Lond B 2002;357:1003-1037.
  3. Rudkin TM, Arnold DL. Proton magnetic resonance spectroscopy for the diagnosos and management of cerebral disorders. Arch Neurol 1999;56:919-926.
  4. Ross B, Bluml S. Magnetic resonance spectroscopy of the human brain. Anat Rec 2001;265:54-84.
  5. Le Bihan D. Looking into the functional architecture of the brain with diffusion MRI. Nature Rev Neurosci 2003;4: 469-480.
  6. Brooks DJ. Morphological and functional imaging studies on the diagnosis and progression of Parkinson's disease. J Neurol 2000;247(Suppl 2):11-18.
  7. Ceballos-Baumann AO. Functional imaging in Parkinson's disease: activation studies with PET, fMRI and SPECT. J Neurol 2003;250(Suppl 1):15-23.
  8. Ogawa S, Lee TM, Nayak As, Glynn P. Oxygenation-sensitive contrast in magnetic reonance image of rodent brain at high magnetic fields. Magn Resonance Med 1990;14:68-78.
  9. Sabatini U, Boulanouar K, Fabre N, Martin F, Carel C, Colonnese C, et al. Cortical motor reorganization in akinetic patients with Parkinson's disease: a functional MRI study. Brain 2000;123:394-403.
  10. Haslinger B, Erhard P, Kampfe N, Boecker H, Rummeny E, Schwaiger M, et al. Event-related functional magnetic resonance imaging in Parkinson's disease before and after levodopa. Brain 2001;124:558-570.
  11. Buhmann C, Glauche V, Sturenburg HJ, Oechsner M, Weiller C, Buchel C. Pharmacologically modulated fMRI: cortical responsiveness to levodopa in drug-naive hemiparkinsonian patients. Brain 2003;126:451-461.
  12. Rowe J, Stephan KE, Friston K, Frackowiak R, Lees A, Passingham R. Attention to action in Parkinson's disease: impaired effective connectivity among frontal cortical regions. Brain 2002;125:276-289.
  13. Mattay VS, Tessitore A, Callicott JH, Bertolino A, Goldberg TE, Chase TN, et al. Dopaminergic modulation of cortical function in patients with Parkinson's disease. Ann Neurol 2002;51:156-164.
  14. Brooks D. Diagnosis and management of atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry 2002;72(Suppl.1):i10-i16.
  15. Davie CA, Wenning GK, Barker GJ, Tofts PS, Kendall BE, Quinn N, et al. Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy. Ann Neurol 1995;37:204-210.
  16. Holshouser BA, Komu M, Moller HE, Zijlmans J, Kolem H, Hinshaw DB Jr, et al. Localized proton NMR spectroscopy in the striatum of patients with idiopathic Parkinson's disease: a multicenter pilot study. Magn Reson Med. 1995;33:589-594.
  17. Clarke CE, Lowry M, Horsamn A. Unchanged basal ganglia N-acetylaspartate and glutamate in idiopathic Parkinson's disease as measured by proton magnetic resonance spectroscopy. Mov Dis 1997;12:297-301.
  18. Federico F, Simone IL, Lucivero V, De Mari M, Giannini P, Iliceto G, et al. Proton magnetic resonance spectroscopy in Parkinson's disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 1997;62:239-242.
  19. Tedeschi G, Litvan I, Bonavita S, Bertolino A, Lundbom N, Patronas N J, et al. Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration. Brain 1997;120:1541-1552.
  20. Choe BY, Park JW, Lee KS, Son BC, Kim MC, Kim BS, et al. Neuronal laterality in Parkinson's disease with unilateral symptom by in vivo 1H magnetic resonance spectroscopy. Invest Radiol. 1998;33:450-455.
  21. Hoang TQ, Bluml S, Dubowitz DJ, Moats R, Kopyov O, Jacques D, et al. Quantitative proton-decoupled 31P MRS and 1H MRS in the evaluation of Huntington's and Parkinson's diseases. Neurology 1998;50:1033-1040.
  22. Hu MT, Taylor-Robinson SD, Chaudhuri KR, Bell JD, Morris RG, Clough C, et al. Evidence for cortical dysfunction in clinically non-demented patients with Parkinson's disease: a proton MR spectroscopy study. J Neurol Neurosurg Psychiatry 1999;67:20-26.
  23. Lucetti C, Del Dotto P, Gambaccini G, Bernardini S, Bianchi MC, Tosetti M, et al. Proton magnetic resonance spectroscopy (1H-MRS) of motor cortex and basal ganglia in de novo Parkinson's disease patients. Neurol Sci 2001;22:69-70.
  24. O'Neill J, Schuff N, Marks WJ Jr, Feiwell R, Aminoff MJ, Weiner MW. Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease. Mov Disord 2002;17:917-927.
  25. Summerfield C, Gomez-Anson B, Tolosa E, Mercader JM, Marti MJ, Pastor P, et al. Dementia in Parkinson disease: a proton magnetic resonance spectroscopy study. Arch Neurol. 2002;59:1415-1420.
  26. Clarke CE, Lowry M. Basal ganglia metabolite concentrations in idiopathic Parkinson's disease and multiple system atrophy measured by proton magnetic resonance spectroscopy. Eur J Neurol 2000;7:661-665.
  27. Axelson D, Bakken IJ, Susann Gribbestad I, Ehrnholm B, Nilsen G, Aasly J. Applications of neural network analyses to in vivo 1H magnetic resonance spectroscopy of Parkinson disease patients. J Magn Reson Imaging. 2002;16:13-20.
  28. Barbiroli B, Martinelli P, Patuelli A, Lodi R, Iotti S, Cortelli P, et al. Phosphorus magnetic resonance spectroscopy in multiple system atrophy and Parkinson's disease. Mov Disord 1999;14:430-435.
  29. Moseley ME, Kucharczyk J, Mintorovitch J, Cohen Y, Kurhanewicz J, Derugin N, et al. Diffusion-weighted MR-imaging of acute stroke.: correlation with T2-weighted an magnetic susceptibility-enhanced imaging in cats. Am L Neuroradiol 1990;11;423-429.
  30. Oshiata T, Oka M, Imon Y, Yamaguchi S, Mimori Y, Nakamura S. Apparent diffusion coefficient measurements in progressive nuclear palsy. Neuroradiology 2000;42:643-647.
  31. Schocke MF, Seppi K, Esterhammer R, Kremser C, Jaschke W, Poewe W, et al. Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. Neurology 2002;58:575-580.
  32. Seppi K, Schocke MF, Esterhammer R, Kremser C, Brenneis C, Mueller J, et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology 2003;60:922-927.
  33. Conturo TE, Lori NF, Cull TS, Akbudak E, Snyder AZ, Shimony JS, et al. Tracking neuronal fibre pathways in the living human brain. Proc Natl Acad Sci USA 1999;96:10422-10427.
  34. Sommer M, Koch MA, Paulus W, Weiller C, Buechel C. Disconnection of speech-relevant brain areas in persistent developmental stuttering. Lancet 2002;360:380-383.
  35. Behrens TE, Johansen-berg H, Woolrich MW, Smith SM, Wheeler-Kingshott CA, Boulby PA, et al. Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging. Nat Neurosci 2003;6:750-757.
  36. Schulz JB, Skalej M, Wedekind D, Luft AR, Abele M, Voigt K, et al. Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy. Ann Neurol 1999;45:65-74.
  37. Gröschel K, Hauser TK, Luft A, Patronas N, Dichgans J, Litvan I, et al. Magnetic resonance imaging-based volumetry differentiates progressive supranuclear palsy from corticobasal degeneration. Neuroimage 2004;21:714-724.
  38. Ashburner J, Friston K. Voxel-based morphometry—the methods. Neuroimage 2000;11:805-821.
  39. Hanyu H, Asano T, Sakurai H, takasaki M, Shindo H, Abe K. Magnetisation transfer measurements of the subcortical grey and white matter in Parkinson's disease with and without dementia in progressive nuclear palsy. Neuroradiology 2001;43:542-546.

Was this article helpful?

0 0

Post a comment